Drug intelligence / Profile preview

PA-300

Development stage: Preclinical
Lead developer: Pathologica

Overview

PA-300 is a lead drug candidate developed by Pathologica LLC. Its preclinical development was significantly supported by approximately $10 million in grant funding from the National Institutes of Health (NIH) to the University of California, San Francisco (UCSF) and Pathologica LLC. This drug is designed to target HIV reservoirs found within macrophages, with the goal of eliminating or reducing these persistent viral hiding places. Clinical trials for PA-300 were projected to commence in 2013.

Beyond the preview

Go deeper on PA-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PA-300.

Explore the full profile